Malignant phyllodes tumours of the breast the case for revising WHO’s ‘full house’ diagnostic criteria /

Phyllodes tumours (PTs) of the breast present diagnostic challenges due to their complex histological features and potential for malignant behaviour. The World Health Organisation (WHO) classification requires the presence of five adverse histological criteria to categorise PTs as malignant, aiming...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Tan Puay Hoon
Ellis Ian O
Allison Kimberly H
Badve Sunil S
Brogi Edi
Callagy Grace
Charafe‐Jauffret Emmanuelle
Chen Chih‐Jung
Chen Yunn‐Yi
Collins Laura C
Cserni Gábor
Djerroudi Lounes
Foschini Maria Pia
Fox Stephen B
Gobbi Helenice
Gudi Mihir
Harada Oi
Jaffer Shabnam
Kulka Janina
Kuroda Hajime
Lakhani Sunil R
Li Xiaoxian
Moriya Takuya
O'Toole Sandra
Pinder Sarah E
Provenzano Elena
Quinn Cecily
Raymond Wendy
Sahin Aysegul A
Schmitt Fernando
et al
Dokumentumtípus: Cikk
Megjelent: 2025
Sorozat:HISTOPATHOLOGY 87 No. 2
Tárgyszavak:
doi:10.1111/his.15455

mtmt:36092275
Online Access:http://publicatio.bibl.u-szeged.hu/37478
Leíró adatok
Tartalmi kivonat:Phyllodes tumours (PTs) of the breast present diagnostic challenges due to their complex histological features and potential for malignant behaviour. The World Health Organisation (WHO) classification requires the presence of five adverse histological criteria to categorise PTs as malignant, aiming to avoid overdiagnosis and improve diagnostic consistency. However, emerging evidence suggests that these strict criteria may underdiagnose tumours with metastatic potential and histological features that would otherwise be considered malignant in soft tissue tumours, leading to significant implications for prognosis and treatment. Recent studies have highlighted cases where tumours classified as borderline PT by WHO criteria exhibited metastatic behaviour, emphasising the need to refine the diagnostic framework. Microscopic criteria used to classify PT also vary among reporting pathologists, resulting in suboptimal reproducibility. This review examines the histological parameters utilised in the classification of malignant PT, highlights existing evidence gaps and analyses international breast pathologist survey data to propose a pragmatic diagnostic approach. We recommend redefining malignant PTs to include cases meeting four of the five WHO criteria, supplemented by comprehensive sampling and clinical context. This approach balances the risk of underdiagnosis with the need for standardised, reproducible diagnostic practices. Future collaborative efforts should focus upon developing evidence‐based, biologically relevant classification systems and leveraging technological advancements to enhance diagnostic precision. These efforts aim to refine classification, improve prognostic accuracy and optimise patient management strategies.
Terjedelem/Fizikai jellemzők:169-182
ISSN:0309-0167